Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

News SummaryMost relevantAll newsSector newsTweets

Lannett Company, Inc. : Lannett Names James Maher to Board of Directors

share with twitter share with LinkedIn share with facebook
share via e-mail
06/03/2013 | 01:55pm CEST

Lannett Company, Inc. (NYSE MKT: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of James M. Maher to its Board of Directors, effective July 1, 2013. Maher joins the board following the retirement of three directors last year. The company's Board will consist of six members, four of whom will be independent directors, including Maher.

Maher, 60, spent his entire professional career with PricewaterhouseCoopers (PwC) LLP. After nearly 40 years with PwC, 30 years as a partner, he retired in June 2012. Most recently, Maher served as the managing partner of PwC's U.S. assurance practice, comprised of more than 1,100 partners and 12,000 staff. Previously, he served as the regional assurance leader for the metro assurance practice. During his tenure at PwC, Maher worked closely with senior management at several multinational companies, dealing extensively with significant acquisitions, divestitures, initial public offerings and secondary offerings. Maher earned a bachelor's degree in Accounting from C. W. Post Campus of Long Island University (now LIU Post).

"Jim brings a strong financial background, especially in the areas of mergers, acquisitions and strategic transactions," said Arthur Bedrosian, Chief Executive Officer. "His deep experience will support our company's continued growth. We welcome Jim to our board as we strive to continue our positive momentum."

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

Robert Jaffe Co., LLC
Robert Jaffe, 424-288-4098

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LANNETT COMPANY, INC.
08/09 LANNETT : Announces Preliminary Fiscal 2017 Fourth Quarter and Full Year Financi..
08/08 LANNETT : Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financi..
08/01 LANNETT : To Present At The Canaccord Genuity 37th Annual Growth Conference On A..
07/19 LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements..
07/18 LANNETT : Appoints Samuel H. Israel As General Counsel
07/17 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Co. Receives Approval for ..
07/17 LANNETT : Appoints Samuel H. Israel As General Counsel
07/14 LANNETT : Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
06/28 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Receives Approval for Addi..
06/26 LANNETT : Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitar..
More news
Financials ($)
Sales 2017 654 M
EBIT 2017 242 M
Net income 2017 10,2 M
Debt 2017 798 M
Yield 2017 -
P/E ratio 2017 417,33
P/E ratio 2018 12,65
EV / Sales 2017 2,11x
EV / Sales 2018 2,09x
Capitalization 583 M
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,2 $
Spread / Average Target 67%
EPS Revisions
Arthur P. Bedrosian Chief Executive Officer & Director
Jeffrey Farber Chairman
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Kristin A. Arnold Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554